FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282964997> ?p ?o ?g. }

• W4282964997 endingPage "CT025" @default.
• W4282964997 startingPage "CT025" @default.
• W4282964997 abstract "Abstract BT8009 is a Bicycle® Toxin Conjugate (BTC™), a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting Nectin-4 tumor antigen, linked to cytotoxin (monomethyl auristatin E [MMAE]) via a valine-citrulline (val-cit) cleavable linker. Due to their small size, BTCs represent a unique therapeutic class, combining the pharmacology normally associated with a biologic with the pharmacokinetic properties of a small molecule. Here, we describe the preliminary monotherapy dose escalation results of the ongoing multicenter Phase I/II clinical trial (NCT04561362) that assesses the safety and tolerability of BT8009 administration in patients with advanced solid tumors associated with Nectin-4 expression, not exposed to enfortumab vedotin. Patients were treated until disease progression or intolerable toxicity, with tumor assessments for response per RECIST taken every two months. Nectin-4 expression levels were measured in tumor tissue. Thirty-four patients were initiated on weekly BT8009 (7 patients at 2.5 mg/m2, 20 patients at 5.0 mg/m2, and 4 patients at 7.5 mg/m2) or biweekly BT8009 (3 patient at 7.5 mg/m2). Baseline demographics were 62% patients were male, 44% and 56% were ECOG 0 and ECOG 1, respectively, median age was 65.5 years. BT8009 exhibits linear pharmacokinetics. The most common treatment-related adverse events were nausea (14 patients, 41%; ≥ G3 1 patient, 3%), fatigue (13 patients, 38%; ≥ G3 2 patients, 6%), anorexia (11 patients, 32%; ≥ G3 0 patients), constipation (10 patients, 29%; ≥ G3 1 patient, 3%) and anemia (10 patients, 29%; ≥ G3 3 patients, 9%). To date, BT8009 had low incidences of ocular disorders (3%), hyperglycemia (6%), neuropathy (6%), and rash (18%). There was 1 dose-limiting toxicity (G3 asthenia) reported at the 7.5 mg/m2 weekly dose level. Six patients (18%) experienced an SAE, with only 1 related SAE (vomiting). Treatment-emergent AEs resulting in treatment discontinuation, dose interruption, or reductions were observed in 2 patients (6%), 11 patients (32%), and 5 patients (15%), respectively. Preliminary confirmed responses observed in patients with urothelial carcinoma (UC) enrolled in the 5 mg/m2 cohort show 4/8 patients with a complete response (CR) or partial response (PR), including 1/8 patients with a CR and 3/8 patients with a PR, and 2/8 patients (25%) with stable disease (SD), reflecting a 50% overall response rate and a 75% disease control rate in UC patients for this cohort. BT8009 exhibits a promising preliminary tolerability profile and preliminary antitumor activity. The molecule will continue to be explored in the current dose-escalation/dose-expansion study of BT8009 monotherapy and in combination with nivolumab. Citation Format: Meredith McKean, Capucine Baldini, Loic Verlingue, Bernard Doger, Gerald Falchook, Antoine Italiano, Julia Lostes, Oscar Reig, Roshawn Watson, Sebastien Hazard, Dominic Smethurst, Giulia Fulci, Hongmei Xu, Phil Jeffery, Kevin Lee, Irene Braña, Sophie Cousin, Elisa Fontana, Hendrik-Tobias Arkenau. BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT025." @default.
• W4282964997 created "2022-06-17" @default.
• W4282964997 creator A5002575629 @default.
• W4282964997 creator A5002720443 @default.
• W4282964997 creator A5007163286 @default.
• W4282964997 creator A5012989377 @default.
• W4282964997 creator A5015836558 @default.
• W4282964997 creator A5023395087 @default.
• W4282964997 creator A5028963681 @default.
• W4282964997 creator A5029689781 @default.
• W4282964997 creator A5036043946 @default.
• W4282964997 creator A5038464425 @default.
• W4282964997 creator A5042185861 @default.
• W4282964997 creator A5060949051 @default.
• W4282964997 creator A5068254469 @default.
• W4282964997 creator A5069777765 @default.
• W4282964997 creator A5071851830 @default.
• W4282964997 creator A5079058944 @default.
• W4282964997 creator A5079422406 @default.
• W4282964997 creator A5089764941 @default.
• W4282964997 creator A5091855392 @default.
• W4282964997 date "2022-06-15" @default.
• W4282964997 modified "2023-10-14" @default.
• W4282964997 title "Abstract CT025: BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression" @default.
• W4282964997 doi "https://doi.org/10.1158/1538-7445.am2022-ct025" @default.
• W4282964997 hasPublicationYear "2022" @default.
• W4282964997 type Work @default.
• W4282964997 citedByCount "1" @default.
• W4282964997 countsByYear W42829649972023 @default.
• W4282964997 crossrefType "journal-article" @default.
• W4282964997 hasAuthorship W4282964997A5002575629 @default.
• W4282964997 hasAuthorship W4282964997A5002720443 @default.
• W4282964997 hasAuthorship W4282964997A5007163286 @default.
• W4282964997 hasAuthorship W4282964997A5012989377 @default.
• W4282964997 hasAuthorship W4282964997A5015836558 @default.
• W4282964997 hasAuthorship W4282964997A5023395087 @default.
• W4282964997 hasAuthorship W4282964997A5028963681 @default.
• W4282964997 hasAuthorship W4282964997A5029689781 @default.
• W4282964997 hasAuthorship W4282964997A5036043946 @default.
• W4282964997 hasAuthorship W4282964997A5038464425 @default.
• W4282964997 hasAuthorship W4282964997A5042185861 @default.
• W4282964997 hasAuthorship W4282964997A5060949051 @default.
• W4282964997 hasAuthorship W4282964997A5068254469 @default.
• W4282964997 hasAuthorship W4282964997A5069777765 @default.
• W4282964997 hasAuthorship W4282964997A5071851830 @default.
• W4282964997 hasAuthorship W4282964997A5079058944 @default.
• W4282964997 hasAuthorship W4282964997A5079422406 @default.
• W4282964997 hasAuthorship W4282964997A5089764941 @default.
• W4282964997 hasAuthorship W4282964997A5091855392 @default.
• W4282964997 hasConcept C112705442 @default.
• W4282964997 hasConcept C126322002 @default.
• W4282964997 hasConcept C143998085 @default.
• W4282964997 hasConcept C197934379 @default.
• W4282964997 hasConcept C2778248108 @default.
• W4282964997 hasConcept C2778375690 @default.
• W4282964997 hasConcept C2780580376 @default.
• W4282964997 hasConcept C71924100 @default.
• W4282964997 hasConcept C90924648 @default.
• W4282964997 hasConceptScore W4282964997C112705442 @default.
• W4282964997 hasConceptScore W4282964997C126322002 @default.
• W4282964997 hasConceptScore W4282964997C143998085 @default.
• W4282964997 hasConceptScore W4282964997C197934379 @default.
• W4282964997 hasConceptScore W4282964997C2778248108 @default.
• W4282964997 hasConceptScore W4282964997C2778375690 @default.
• W4282964997 hasConceptScore W4282964997C2780580376 @default.
• W4282964997 hasConceptScore W4282964997C71924100 @default.
• W4282964997 hasConceptScore W4282964997C90924648 @default.
• W4282964997 hasIssue "12_Supplement" @default.
• W4282964997 hasLocation W42829649971 @default.
• W4282964997 hasOpenAccess W4282964997 @default.
• W4282964997 hasPrimaryLocation W42829649971 @default.
• W4282964997 hasRelatedWork W2002502340 @default.
• W4282964997 hasRelatedWork W2022556905 @default.
• W4282964997 hasRelatedWork W2070441327 @default.
• W4282964997 hasRelatedWork W2074207917 @default.
• W4282964997 hasRelatedWork W2154883587 @default.
• W4282964997 hasRelatedWork W2394317912 @default.
• W4282964997 hasRelatedWork W4205587618 @default.
• W4282964997 hasRelatedWork W4251165208 @default.
• W4282964997 hasRelatedWork W4296087748 @default.
• W4282964997 hasRelatedWork W4366822339 @default.
• W4282964997 hasVolume "82" @default.
• W4282964997 isParatext "false" @default.
• W4282964997 isRetracted "false" @default.
• W4282964997 workType "article" @default.